Breaking News Instant updates and real-time market news.

EXAS

Exact Sciences

$45.96

0.96 (2.13%)

, ROK

Rockwell Automation

$177.55

0.22 (0.12%)

07:30
09/25/17
09/25
07:30
09/25/17
07:30

Unusual put flow in option market yesterday

Notable put activity was cited Friday in EXACT Sciences (EXAS), Rockwell Automation (ROK), and DaVita (DVA).

EXAS

Exact Sciences

$45.96

0.96 (2.13%)

ROK

Rockwell Automation

$177.55

0.22 (0.12%)

DVA

DaVita

$57.49

-3.77 (-6.15%)

  • 30

    Nov

EXAS Exact Sciences
$45.96

0.96 (2.13%)

09/21/17
LEER
09/21/17
NO CHANGE
Target $50
LEER
Outperform
Exact Sciences price target raised to $50 from $45 at Leerink
Leerink analyst Puneet Souda raised his price target for Exact Sciences to $50 from $45 as he believes Cologuard ramp still remains under-appreciated longer-term. As part of its ongoing execution, Exact Sciencesis taking a number of steps to help accelerate the ramp and sales leverage even further, he adds, reiterating an Outperform rating on the shares.
07/26/17
CHLM
07/26/17
NO CHANGE
Target $46
CHLM
Buy
Exact Sciences price target raised to $46 from $41 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich raised his price target for Exact Sciences to $46 from $41 as "exceptional" Cologuard volume drives Q2 results well above expectations, while "significant" guidance raise suggests more to come. The analyst reiterates a Buy rating on the shares.
08/24/17
LEER
08/24/17
NO CHANGE
Target $45
LEER
Outperform
Exact Sciences poised to drive 'significant' uptake long-term, says Leerink
Leerink analyst Puneet Souda reiterates an Outperform rating on Exact Sciences given that the adoption of its Colorectal Cancer screening test Cologuard in the 80M target U.S. population remains highly underpenetrated at just about 2% with expectations to reach 30% or even more longer-term. The analyst also raised his price target on the shares to $45 from $44.
09/07/17
ADAM
09/07/17
NO CHANGE
Target $45
ADAM
Buy
Exact Sciences remains a top pick for 2017, says Canaccord
Canaccord analyst Mark Massaro said Exact Sciences remains a top pick for 2017 after the company delivered another upbeat investor presentation. He cited the company's commentary on new hiring, its liquid biopsy development plans, and advertising spending. Massaro reiterated his Buy rating and $45 price target on Exact Sciences shares.
ROK Rockwell Automation
$177.55

0.22 (0.12%)

04/19/17
GABE
04/19/17
UPGRADE
GABE
Hold
Rockwell Automation upgraded to Hold from Sell at Gabelli
Gabelli upgraded Rockwell Automation to Hold with a $164 per share 2018 PMV due to strength in the consumer and automotive segments and potential M&A.
04/04/17
WELS
04/04/17
NO CHANGE
WELS
ABB acquisition should provide support for Rockwell Automation, says Wells Fargo
Following the announcement that ABB (ABB) plans to acquire Bernecker & Rainer Industrie- Elektronik, Wells Fargo analyst Richard Kwas says the deal should provide support for Rockwell Automation's (ROK) shares, and should be a positive read through for the latter. The acquisition fills gaps for ABB in discrete automation, the analyst notes, adding that ABB could become a "more formidable competitor" in discrete. Separately, Kwas acknowledges that he had thought that Bernecker & Rainer Industrie- Elektronik may have been a "good fit" for Emerson (EMR), which he expects to execute additional M&A later in the year.
07/27/17
JPMS
07/27/17
UPGRADE
Target $153
JPMS
Neutral
Rockwell Automation upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst C. Stephen Tusa upgraded Rockwell Automation to Neutral saying the company reported another quarter of "strong organic growth and solid fundamentals." In a research note partially titled "We Were Wrong," the analyst maintains a $153 price target for the shares.
07/27/17
07/27/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Boeing (BA) was upgraded to Outperform from Neutral at Credit Suisse, to Buy from Neutral at BofA/Merrill, to Neutral from Sell at Goldman Sachs, and to Sector Perform from Underperform at RBC Capital. 2. State Street (STT) upgraded to In Line from Underperform at Evercore ISI with analyst Glenn Schorr citing improved execution and expects share to perform inline with the group despite continued fee pressure and competitive threats. 3. Vermilion Energy (VET) upgraded to Outperform from Sector Perform at RBC Capital. 4. DDR Corp. (DDR) upgraded to Buy from Hold at Deutsche Bank with analyst Vin Chao saying new management's progress towards balance sheet and disposition plans has much improved FFO visibility. 5. Rockwell Automation (ROK) upgraded to Neutral from Underweight at JPMorgan with analyst C. Stephen Tusa saying the company reported another quarter of "strong organic growth and solid fundamentals." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
DVA DaVita
$57.49

-3.77 (-6.15%)

06/26/17
06/26/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. GrubHub (GRUB) downgraded to Equal Weight from Overweight by Morgan Stanley analyst John Glass, who lowered his price target to $43 from $47. The firm's survey results indicate 26% of Amazon (AMZN) Prime members have tried Amazon Restaurants in the past 6 months, and other players such as UberEATS and YelpEat24 are emerging, which longer-term will reduce GrubHub's profitability and cash flow, the analyst argues. 2. Stratasys (SSYS) downgraded to Sell from Neutral by Goldman Sachs analyst Matthew Cabral, who noted that the shares are up 67% year-to-date while competition is ramping and price pressure is mounting. 3. DaVita (DVA) downgraded to Hold from Buy by Jefferies analyst Chris Cooper, who cites slowing treatment growth and the "tight" rate environment. 4. Agios Pharmaceuticals (AGIO) downgraded to Neutral by Janney Capital analyst Debjit Chattopadhyay, who believes peak sales estimates for its acute myeloid leukemia treatment are likely to move lower over time. 5. American Electric (AEP) was downgraded to Neutral from Buy while Ameren (AEE) and WEC Energy (WEC) were both downgraded to Sell from Neutral at Goldman Sachs, where analyst Michael Lapides downgraded the Utilities sector to Cautious from Neutral saying valuations now appear stretched while earnings growth appears relatively normal. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/26/17
JEFF
06/26/17
DOWNGRADE
Target $70
JEFF
Hold
DaVita downgraded to Hold from Buy at Jefferies
Jefferies analyst Chris Cooper downgraded DaVita to Hold citing slowing treatment growth and the "tight" rate environment. The analyst believes a less competitive cost base and patient steering allegations are hindering the company's rate negotiations. He sees risk to consensus estimates and keeps a $70 price target for DaVita shares.
12/13/16
12/13/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Deutsche Bank analyst Bill Schmitz downgraded Procter & Gamble (PG) to Hold citing a lack of catalysts over the next few quarters. The analyst lowered his price target for P&G shares to $90 from $95 but remains positive on P&G's medium to long-term opportunity. Schmitz also downgraded Coca-Cola (KO) to Hold saying that while CEO James Quincey "is the right person for the turnaround job," near-term stock outperformance will be limited by investor migration out of staples, wellness related consumption headwinds and likely negative earnings revisions. The analyst cut his price target for Coca-Cola shares to $44 from $48. 2. Barclays analyst Karen Short downgraded GNC Holdings (GNC) to Underweight saying the company's recent strategy change and press reports indicating that at least some potential foreign buyers are not interested in the U.S. assets make a potential takeover unlikely. 3. RBC Capital downgraded Viacom (VIAB) to Underperform from Sector Perform after the company announced that it would no longer pursue a merger with CBS (CBS). Wedbush analyst James Dix also downgraded Viacom to Neutral after National Amusements withdrew support for a merger with CBS. 4. Craig-Hallum analyst Chad Bennett downgraded Model N (MODN) to Hold saying the "risks outweigh the benefits" following the company's acquisition of primary competitor Revitas. 5. Baird analyst Whit Mayo downgraded DaVita (DVA) to Neutral from Outperform after CMS issued its notice with respect to third-party premium support for ESRD patients enrolling in Exchange plans, which he views as potentially putting the company's entire $230M HIX tailwind at risk. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/13/16
12/13/16
DOWNGRADE
Target $69

Neutral
DaVita downgraded to Neutral after CMS guidance at Baird
As previously reported, Baird analyst Whit Mayo downgraded DaVita to Neutral from Outperform after CMS issued its notice with respect to third-party premium support for ESRD patients enrolling in Exchange plans, which he views as potentially putting the company's entire $230M HIX tailwind at risk. Mayo, who also cites the stock's 20% bounce off of its bottom and the company's "tepid" organic growth, sees DaVita shares "trading sideways" in the near-term. He raised his price target on DaVita to $69 from $68.

TODAY'S FREE FLY STORIES

WAC

Walter Investment

$0.51

-0.0056 (-1.09%)

10:24
10/21/17
10/21
10:24
10/21/17
10:24
Hot Stocks
Walter Investment reaches agreement on financial restructuring »

Walter Investment has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMST

TimkenSteel

$17.57

0.19 (1.09%)

10:18
10/21/17
10/21
10:18
10/21/17
10:18
Hot Stocks
Tentative agreement between TimkenSteel, United Steelworkers voted down »

TimkenSteel employees who…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

AGEN

Agenus

$4.33

-0.14 (-3.13%)

, GSK

GlaxoSmithKline

$40.84

-0.26 (-0.63%)

10:15
10/21/17
10/21
10:15
10/21/17
10:15
Hot Stocks
FDA approves GlaxoSmithKline shingles vaccine with Agenus QS-21 Stimulon »

Agenus (AGEN) has…

AGEN

Agenus

$4.33

-0.14 (-3.13%)

GSK

GlaxoSmithKline

$40.84

-0.26 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 06

    Nov

MS

Morgan Stanley

$50.68

0.89 (1.79%)

10:06
10/21/17
10/21
10:06
10/21/17
10:06
Periodicals
Another 20% gain in Morgan Stanley stock likely, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

SSNLF

Samsung

10:02
10/21/17
10/21
10:02
10/21/17
10:02
Periodicals
Samsung has lots of upside driven by chips/screens, Barron's says »

Samsung stock is up 50%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 30

    Oct

DLAKY

Lufthansa

$30.28

0.2 (0.66%)

09:56
10/21/17
10/21
09:56
10/21/17
09:56
Periodicals
Lufthansa has more room to climb, Barron's says »

Amid competitor's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$59.90

0.12 (0.20%)

, DAL

Delta Air Lines

$53.27

1 (1.91%)

09:51
10/21/17
10/21
09:51
10/21/17
09:51
Periodicals
Market pounds United, sees American/Delta as possibly safe bets, Barron's says »

United Continental's…

UAL

United Continental

$59.90

0.12 (0.20%)

DAL

Delta Air Lines

$53.27

1 (1.91%)

AAL

American Airlines

$51.93

0.42 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 26

    Oct

  • 01

    Nov

CZR

Caesars

$12.20

0.15 (1.24%)

09:45
10/21/17
10/21
09:45
10/21/17
09:45
Periodicals
Caesars looks ready to grow again, Barron's says »

After a disastrous 2008…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 08

    Nov

DWDP

DowDuPont

$71.18

0.29 (0.41%)

09:40
10/21/17
10/21
09:40
10/21/17
09:40
Periodicals
DowDuPont shares likely to return as much as 30% over next year, Barron's says »

If DowDuPont can cut $3B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COH

Coach

$40.35

0.88 (2.23%)

09:29
10/21/17
10/21
09:29
10/21/17
09:29
Periodicals
Coach shares look undervalued, could rise nearly 30%, Barron's says »

Coach, which has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$96.50

1.8 (1.90%)

, MOH

Molina Healthcare

$64.40

0.76 (1.19%)

09:24
10/21/17
10/21
09:24
10/21/17
09:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

CNC

Centene

$96.50

1.8 (1.90%)

MOH

Molina Healthcare

$64.40

0.76 (1.19%)

CI

Cigna

$191.42

3.2 (1.70%)

ANTM

Anthem

$194.69

1.49 (0.77%)

AET

Aetna

$160.84

3.2 (2.03%)

HNT

Health Net

HUM

Humana

$245.81

3.12 (1.29%)

UNH

UnitedHealth

$207.49

4.24 (2.09%)

WCG

WellCare

$180.52

3.28 (1.85%)

CYH

Community Health

$6.44

0.24 (3.87%)

HCA

HCA Healthcare

$81.05

1.26 (1.58%)

LPNT

LifePoint

$58.35

0.5 (0.86%)

THC

Tenet

$14.66

1.31 (9.81%)

UHS

Universal Health

$112.85

2.31 (2.09%)

GOOG

Alphabet

$988.20

3.75 (0.38%)

GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

MSFT

Microsoft

$78.81

0.9 (1.16%)

FB

Facebook

$174.98

0.42 (0.24%)

INTC

Intel

$40.43

0.34 (0.85%)

IBM

IBM

$162.07

1.17 (0.73%)

MAR

Marriott

$115.02

-0.18 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 26

    Oct

  • 26

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 02

    Nov

  • 02

    Nov

  • 03

    Nov

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 08

    Nov

  • 15

    Nov

  • 15

    Nov

  • 29

    Nov

  • 30

    Nov

  • 18

    Mar

ETFC

E-Trade

$43.20

-0.49 (-1.12%)

08:55
10/21/17
10/21
08:55
10/21/17
08:55
Conference/Events
E-Trade to hold an education day »

Chicago Education Day is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

08:45
10/21/17
10/21
08:45
10/21/17
08:45
General news
Breaking General news story  »

New York Federal Reserve…

FB

Facebook

$174.98

0.42 (0.24%)

, AMZN

Amazon.com

$982.91

-3.7 (-0.38%)

08:25
10/21/17
10/21
08:25
10/21/17
08:25
Periodicals
Regulators inquiries fuel speculation about big tech breakup, Barron's says »

Facebook (FB), Amazon…

FB

Facebook

$174.98

0.42 (0.24%)

AMZN

Amazon.com

$982.91

-3.7 (-0.38%)

GOOG

Alphabet

$988.20

3.75 (0.38%)

GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 26

    Oct

  • 26

    Oct

  • 01

    Nov

  • 08

    Nov

  • 15

    Nov

  • 29

    Nov

  • 18

    Mar

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

07:58
10/21/17
10/21
07:58
10/21/17
07:58
Hot Stocks
DBV believes FDA suggested continue moving forward with Viaskin »

DBV Technologies (DBVT)…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

04:55
10/21/17
10/21
04:55
10/21/17
04:55
General news
Breaking General news story  »

New York Federal Reserve…

ETFC

E-Trade

$43.20

-0.49 (-1.12%)

04:55
10/21/17
10/21
04:55
10/21/17
04:55
Conference/Events
E-Trade to hold an education day »

Chicago Education Day is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.